Total trials
362
Active
73
Phase 3
36
Total enrollment
1,381,837
Pipeline matrix
Showing 40 of 56 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Progesterone Vaginal Product | — | — | — | — | — | 1 | |
| Etidronate | — | — | — | — | 2 | ||
| Hydroxychloroquine | — | — | — | — | 2 | ||
| Imatinib | — | — | — | — | 2 | ||
| Aspirin | — | — | — | — | 2 | ||
| Ceftriaxone | — | — | — | — | — | 1 | |
| Moxifloxacin or Levofloxacin | — | — | — | — | — | 1 | |
| Piperacillin-tazobactam | — | — | — | — | — | 1 | |
| Ceftaroline | — | — | — | — | — | 1 | |
| Amoxicillin-clavulanate | — | — | — | — | — | 1 | |
| Standard course macrolide | — | — | — | — | — | 1 | |
| Extended course macrolide | — | — | — | — | — | 1 | |
| Fixed-duration Hydrocortisone | — | — | — | — | — | 1 | |
| Shock-dependent hydrocortisone | — | — | — | — | — | 1 | |
| Fixed-duration higher dose Hydrocortisone | — | — | — | — | — | 1 | |
| Five-days oseltamivir | — | — | — | — | — | 1 | |
| Ten-days oseltamivir | — | — | — | — | — | 1 | |
| Lopinavir / Ritonavir | — | — | — | — | — | 1 | |
| Hydroxychloroquine + lopinavir/ritonavir | — | — | — | — | — | 1 | |
| Ivermectin | — | — | — | — | — | 1 | |
| Interferon beta-1a | — | — | — | — | — | 1 | |
| Anakinra | — | — | — | — | — | 1 | |
| Tocilizumab | — | — | — | — | — | 1 | |
| Sarilumab | — | — | — | — | — | 1 | |
| Local standard venous thromboprophylaxis | — | — | — | — | — | 1 | |
| Therapeutic dose anticoagulation | — | — | — | — | — | 1 | |
| Conventional low dose thromboprophylaxis | — | — | — | — | — | 1 | |
| Intermediate dose thromboprophylaxis | — | — | — | — | — | 1 | |
| Continuation of therapeutic dose anticoagulation | — | — | — | — | — | 1 | |
| Convalescent plasma | — | — | — | — | — | 1 | |
| Delayed administration of convalescent plasma | — | — | — | — | — | 1 | |
| Vitamin C | — | — | — | — | — | 1 | |
| P2Y12 inhibitor | — | — | — | — | — | 1 | |
| Simvastatin | — | — | — | — | — | 1 | |
| Eritoran | — | — | — | — | — | 1 | |
| Apremilast | — | — | — | — | — | 1 | |
| Angiotensin converting enzyme inhibitor | — | — | — | — | — | 1 | |
| Angiotensin Receptor Blockers | — | — | — | — | — | 1 | |
| ARB + DMX-200 | — | — | — | — | — | 1 | |
| Cysteamine | — | — | — | — | — | 1 |
16 more active programs hidden
Next readouts
- 2025-12
- 2026-02
- 2026-11-01
- 2026-12
- 2026-12-31
- 2027-03-29
- 2027-11
- 2027-12
- 2028-01
- 2028-06-01
Top conditions
- Breast Cancer15
- Coronary Artery Disease11
- Hypertension10
- Delirium7
- Cardiovascular Diseases6
- Heart Failure6
- Prostate Cancer6
- Schizophrenia5
Frequently asked questions about UMC Utrecht
- How many clinical trials does UMC Utrecht have on ClinicalTrials.gov?
- UMC Utrecht is listed as the lead sponsor on 362 clinical trials in ClinicalTrials.gov, 73 of which are currently active (recruiting, enrolling, or ongoing).
- How many of UMC Utrecht's trials are in Phase 3?
- 36 of UMC Utrecht's trials are in Phase 3, spread across 56 active drug programs.
- What therapeutic areas does UMC Utrecht focus on?
- UMC Utrecht's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Coronary Artery Disease, Hypertension, Delirium, Cardiovascular Diseases.
- When are UMC Utrecht's next clinical trial readouts?
- UMC Utrecht has 10 upcoming primary-completion readouts tracked here; the soonest is “Luteal Phase Support in IUI MOH Treatment Luteal Phase Support in IUI MOH Treatment”, expected around 2025-12.